Log in to your Inderes Free account to see all free content on this page.

Zelluna

Less than 1K followers

ZLNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

23.4.

2026

General meeting '26

7.5.

2026

Interim report Q1'26

20.8.

2026

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release2/20/2026, 1:30 PM

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

Regulatory press release2/12/2026, 6:00 AM

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission

Regulatory press release2/11/2026, 7:00 AM

ZLNA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/11/2026, 7:00 AM

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Regulatory press release2/5/2026, 12:30 PM

Zelluna ASA - Grant of Share Options

Regulatory press release2/5/2026, 8:30 AM

Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation

Regulatory press release2/3/2026, 7:00 AM

ZLNA: Zelluna promotes Emilie Gauthy to Chief Technology Officer

Regulatory press release2/3/2026, 7:00 AM

Zelluna promotes Emilie Gauthy to Chief Technology Officer

Regulatory press release1/15/2026, 11:22 AM

Zelluna ASA: Approval and publication of prospectus

Regulatory press release12/17/2025, 4:26 PM

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours

Regulatory press release12/16/2025, 11:36 AM

ZLNA: Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Regulatory press release12/16/2025, 11:36 AM

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Press release12/15/2025, 1:33 PM

BioStock: Zelluna: killer cells tackling the solid cancer bottleneck

Regulatory press release12/12/2025, 12:02 PM

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial

Regulatory press release12/9/2025, 8:36 AM

Zelluna ASA: Cancellation of subsequent repair offering

Regulatory press release12/9/2025, 7:22 AM

ZLNA: Financial calendar

Regulatory press release12/8/2025, 5:36 PM

Zelluna ASA - Mandatory notification of trade

Regulatory press release12/8/2025, 5:36 PM

Zelluna ASA - Mandatory notification of trade

Regulatory press release12/8/2025, 12:52 PM

Zelluna ASA: New share capital registered

Regulatory press release11/28/2025, 6:50 AM

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.